1. Buzon L, Bernardino JI, Galindo Puerto MJ, Martin-Torres J, et al.
   Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.
   AIDS 2025.
   


2. Rolle C, Achhra A, Harbison C, Finkel D, et al.
   Combined use of ibalizumab and lenacapavir for the treatment of multidrug-resistant HIV-1: A case series.
   Clin Infect Dis 2025.
   


3. Short WR, Ogbuagu OE.
   New strategies for a vexing problem: injectables to the rescue for people with Multidrug-Resistant HIV.
   Clin Infect Dis 2025.
   


4. Hallmark CJ, France AM, Linley L, Lyss SB, et al.
   Characteristics of HIV Time-Space Alerts in the United States, 2018-2021.
   J Acquir Immune Defic Syndr 2025.
   


5. Drumright LN, Delaney JA, Crawford T, Whitney BM, et al.
   Longitudinal associations between internalized HIV stigma and lower HIV antiretroviral therapy adherence among people with HIV.
   J Acquir Immune Defic Syndr 2025.
   


6. Laxmeshwar C, Hegde A, Dange A, Mariyappan K, et al.
   Virtual model for HIV self-testing demand generation and kit distribution: Results from the STAR III study in India.
   J Acquir Immune Defic Syndr 2025.
   


7. Nguyen T, Chae JW, Ziemba L, Coletti A, et al.
   Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results from IMPAACT 2010/VESTED.
   J Acquir Immune Defic Syndr 2025.
   


8. Wamakima B, Diouf K, Modest A, Macharia A, et al.
   Pre-eclampsia Rates in Women with and without HIV in Modern ART Era in Botswana.
   J Acquir Immune Defic Syndr 2025.
   


9. Umutoni V, Eavou R, Almirol E, Neumann MS, et al.
   A Community Located Insurance Navigation Intervention to link Sexual and Gender Minorities in Status Neutral Care: Results from the NICE Randomized Controlled Trial.
   J Acquir Immune Defic Syndr 2025.
   


10. Mathur T, Ahmed S, Parthasarathy D, Herschhorn A, et al.
    Highly efficient production of HIV-1(AD8) gp120 in mammalian cells.
    J Virol 2025.
    


11. Mayer KH, Beyrer C, Cohen MS, El-Sadr WM, et al.
    Challenges and opportunities in developing integrated sexual and reproductive health programmes.
    Lancet 2025;406:2168-2190.
    


12. Meyer-Rath G, Jamieson L, Mudimu E, Snyman K, et al.
    Who pays and what pays off in sexual and reproductive health? A review of the cost and cost-effectiveness of interventions and implications for future funding and markets.
    Lancet 2025;406:2152-2167.
    


13. Peters RPH, Grinsztejn B, Celum C, Mayer KH, et al.
    Innovations in the biomedical prevention, diagnosis, and service delivery of HIV and other sexually transmitted infections.
    Lancet 2025;406:2133-2151.
    


14. Grulich AE, Mercer CH, Sturrock B, Baral S, et al.
    Partial progress in sexual and reproductive health and rights: the influence of sociocultural, behavioural, structural, and technological changes on epidemiological trends.
    Lancet 2025;406:2100-2118.
    


15. Ngema N.
    A rights-based imperative for young women.
    Lancet 2025;406:2038-2040.
    


16. Kityo C, Mambule IK, Musaazi J, Sokhela S, et al.
    Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.
    Nat Med 2025.
    


17. Sarkar S.
    HIV: Five children in India are infected from contaminated blood donations.
    BMJ 2025;391:r2310.
    

Display articles in

• Abstract format